Sun Pharmaceutical Industries Limited
All news and filings related to Sun Pharmaceutical Industries Limited.
View all news & filings- High impact
Sun Pharma Assigned Baa1 (Moody's) & BBB+ (S&P) Ratings; Organon Acquisition Key Factor
Sun Pharma received Baa1 (stable) from Moody's and preliminary BBB+ (stable) from S&P. Ratings reflect strong business/financial profile and proposed $11.75 billion Organon acquisition, expected to close by March 2027. Acquisition to boost scale, diversification, and revenue, with integration risks acknowledged. Leverage to increase temporarily, then deleverage.
Read the summary - Low impact
Sun Pharma Schedules Analyst/Institutional Investor Meetings from Sept 10-22
Sun Pharmaceutical Industries Limited will attend several analyst and institutional investor meetings from September 10 to September 22, 2026. The meetings include the UBS India Summit, Jefferies India Forum, Kotak Healthcare Forum, J.P. Morgan India Conference, and Anand Rathi G-200 Summit. No UPSI will be disclosed.
Read the summary - Medium impact
Sun Pharma Joins White House Ceremony for U.S. Medicines Pricing Commitments
Sun Pharma committed to extending Most Favored Nation (MFN) pricing to state Medicaid programs and for future innovative medicine launches. The company also secured a delay in Section 232 tariffs on innovative pharmaceutical products for over two years as part of agreements announced at a White House ceremony on September 1, 2026.
Read the summary - Low impact
Sun Pharma Publishes Newspaper Ads for Postal Ballot/E-Voting
Sun Pharmaceutical Industries Limited published newspaper advertisements on August 26, 2026, regarding Postal Ballot/E-Voting. The ads appeared in Financial Express (English) and its Gujarati edition. Copies are available on the company's website.
Read the summary - Low impact
Sun Pharma Seeks Shareholder Approval for Promoter Group Reclassification
Sun Pharma is conducting a postal ballot and e-voting for shareholders to approve the reclassification of three individuals from the 'Promoter Group' to the 'Public' category. The voting period is from August 28 to September 26, 2026. This change will adjust promoter holding to 52.68% and public holding to 47.32%.
Read the summary - Low impact
Sun Pharma Schedules Analyst/Institutional Investor Meeting for Sept 1
Sun Pharma will hold an analyst/institutional investor meeting on September 1, 2026, in Mumbai. The meeting will be a mix of group and one-on-one sessions. No Unpublished Price Sensitive Information (UPSI) will be shared.
Read the summary - Medium impact
Sun Pharma Wins Lipitor Antitrust Litigation in US Appeals Court
Sun Pharma and its subsidiaries have won an antitrust lawsuit in the US related to generic Lipitor. The US Court of Appeals affirmed a lower court's ruling, granting summary judgment in favor of Sun Pharma and denying class certification to plaintiffs. This outcome significantly concludes the litigation.
Read the summary - Low impact
Sun Pharma Receives No-Objection for Promoter Reclassification from NSE and BSE
Sun Pharmaceutical Industries Limited received No-Objection Letters from NSE and BSE on August 06, 2026, for reclassifying Krishna Vrundavandas Valia, Sudhir Vrundavandas Valia, and Raksha Sudhir Valia from 'Promoter Group' to 'Public' category. This is in accordance with SEBI Regulation 31A.
Read the summary - High impact
Sun Pharma Q1 FY27 Sales Grow 10.1% to ₹15,183.6 Crore; Net Profit at ₹2,894.8 Crore
Sun Pharma reported Q1 FY27 sales of ₹15,183.6 crore, up 10.1%. Net profit stood at ₹2,894.8 crore. The company incurred ₹161.7 crore in acquisition costs for Organon, which is expected to close by early 2027. India formulations grew 16% to ₹5,474.9 crore. US business sales declined 9.7% to $427 million.
Read the summary - Low impact
Sun Pharma Schedules Investor Meetings from Aug 10-13, 2026
Sun Pharma will hold investor meetings from August 10-13, 2026, in Mumbai. Meetings are scheduled with Nirmal Bang, Emkay, and Equirus. No UPSI will be disclosed. The schedule is subject to change.
Read the summary - Medium impact
Sun Pharma's Long-Term Bank Facilities Reaffirmed at CRISIL AAA/Stable
CRISIL Ratings has reaffirmed Sun Pharmaceutical Industries Limited's long-term bank facilities rating at ‘CRISIL AAA/Stable’. The ‘Rating Watch with Developing Implications’ status has been removed. This follows a previous rating of ‘CRISIL AAA’ placed on watch on 07 May 2026.
Read the summary - Low impact
Sun Pharma Publishes Q1 FY27 Unaudited Financial Results in Newspapers
Sun Pharmaceutical Industries Limited published its unaudited financial results for the quarter ended 30 June 2026. Advertisements appeared in the Financial Express on 01 August 2026. The results are filed with stock exchanges and available on the company's website.
Read the summary - Low impact
Sun Pharma's 34th AGM Concludes on July 31, 2026; All Resolutions Passed
Sun Pharmaceutical Industries Limited's 34th AGM concluded on July 31, 2026. Shareholders approved all resolutions presented in the AGM Notice dated July 6, 2026. The voting results and scrutinizer's report are available on the company website.
Read the summary - Medium impact
Sun Pharma's 34th AGM Approves Final Dividend, Director Re-appointments, and New Appointments
Sun Pharma's 34th AGM on July 31, 2026, approved the financial statements for FY26 and a final dividend of ₹5.00 per share. Shareholders re-appointed Mr. Aalok Shanghvi and approved his revised remuneration. Dr. Andreas Busch was appointed as an Independent Director from May 12, 2026, to May 11, 2031.
Read the summary - Low impact
Sun Pharma Q1 FY27 Earnings Call Audio Recording Available
Sun Pharma has released the audio recording of its Q1 FY27 earnings call held on July 31, 2026. The recording is available on the company's website.
Read the summary - Low impact
Sun Pharma Board Meeting Concludes on July 31, 2026
Sun Pharmaceutical Industries Limited's Board Meeting concluded on July 31, 2026. The meeting started at 10:50 AM and finished at 3:40 PM after a break.
Read the summary - High impact
Sun Pharma Q1FY27 Sales Up 10.1% to ₹151,836 Million; Net Profit at ₹28,948 Million
Sun Pharma reported Q1 FY27 consolidated sales of ₹151,836 million, up 10.1% YoY. Net profit rose to ₹28,948 million. India formulation sales grew 16% to ₹54,749 million. Global Innovative Medicines sales increased 12.8% to US$ 351 million. The acquisition of Organon & Co. is on track to close in early 2027.
Read the summary - Medium impact
Sun Pharma gets Brazil approval for semaglutide injection for Type 2 Diabetes
Sun Pharma received ANVISA approval to manufacture and market semaglutide injection in Brazil for type 2 diabetes. The product will be launched in partnership with Hypera Pharma. The Brazilian semaglutide market is approximately USD 413 million.
Read the summary - Low impact
Sun Pharma Announces Special Window for Physical Share Transfer
Sun Pharma has opened a special window for physical share transfers, valid from February 5, 2026, to February 4, 2027. This initiative aims to process transfers of shares sold or purchased before April 1, 2019, including previously rejected requests. Advertisements were published on July 28, 2026.
Read the summary - Medium impact
Sun Pharma Partner Philogen Resubmits Nidlegy MAA to EMA for Melanoma Treatment
Philogen, partnered with Sun Pharma, has resubmitted a Marketing Authorization Application to the EMA for Nidlegy. The application is for the neoadjuvant treatment of melanoma. This resubmission follows updated clinical data from the Phase III PIVOTAL study with a longer patient follow-up.
Read the summary - Medium impact
Sun Pharma's Proposed Acquisition of Organon Moves Forward as Shareholders Approve Merger
Organon shareholders approved the merger transaction with Sun Pharma. This is a key milestone for Sun Pharma's acquisition of Organon, which will become a wholly owned subsidiary. The deal is subject to regulatory approvals.
Read the summary - Medium impact
Sun Pharma Secures SAHPRA Approval for Generic Semaglutide Injection in South Africa
Sun Pharma received SAHPRA approval to manufacture and market generic semaglutide injection in South Africa for type 2 diabetes. The product will be available in two strengths and launched in the coming days. This follows approval in India and aims to improve access to treatments.
Read the summary - Low impact
Sun Pharma to announce Q1 FY27 results on July 31, 2026; earnings call scheduled
Sun Pharmaceutical Industries Limited will announce its first quarter results for the period ending June 30, 2026, on July 31, 2026. An earnings call is scheduled for the same day at 06:30 pm IST, where senior management will discuss the company's performance. Details for participation and webcast will be available on the company website.
Read the summary - Low impact
Sun Pharma Submits Confirmation Certificate for Q1FY27 Dematerialisation
Sun Pharmaceutical Industries Limited received a confirmation certificate for the quarter ended June 30, 2026, from its Registrar & Share Transfer Agent, MUFG Intime India Private Limited. The certificate confirms the processing of dematerialised securities and their listing on stock exchanges.
Read the summary - Low impact
Sun Pharma to hold 34th AGM on July 31, 2026; Annual Report 2025-26 released
Sun Pharma released its Annual Report 2025-26 and announced its 34th Annual General Meeting (AGM) on July 31, 2026. Remote e-voting begins July 27 and ends July 30. The cut-off date for voting eligibility is July 24, 2026.
Read the summary - Medium impact
Sun Pharma to Acquire Innovcare Lifesciences for ₹271.2 Crore, Strengthening Portfolio
Sun Pharma will acquire 100% of Innovcare Lifesciences for ₹271.2 Crores cash. Innovcare markets pharmaceutical, nutraceutical, and cosmeceutical products. The acquisition is expected to be completed by 31 July 2026, strengthening Sun Pharma's product portfolio.
Read the summary - Low impact
Sun Pharma Publishes Newspaper Ads on IEPF Share Transfer & Unclaimed Dividends
Sun Pharma published newspaper ads on June 16, 2026, concerning the transfer of equity shares and unclaimed dividends to the IEPF Account as per the Companies Act, 2013. Shareholders are urged to claim unpaid dividends by August 31, 2026, to avoid transfer to IEPF. Details are on the company website.
Read the summary - Low impact
Sun Pharma Independent Director Gautam Doshi Arrested; No Company Impact Expected
Sun Pharmaceutical Industries Limited announced that its Independent Director, Mr. Gautam Doshi, has been arrested. The company clarified that the matter is unrelated to Sun Pharma and is not expected to impact the company or its board operations. Sun Pharma will monitor developments and take further action as needed.
Read the summary - Medium impact
Sun Pharma Sets July 7, 2026 as Record Date for ₹5 Final Dividend; AGM on July 31
Sun Pharma's 34th AGM is on July 31, 2026. The record date for a ₹5 final dividend for FY25-26 is July 7, 2026. Dividend payment is expected by August 7, 2026. Shareholders must update contact details by July 7, 2026, for TDS purposes.
Read the summary - Low impact
Sun Pharma Schedules 34th AGM for July 31, Sets Record Date for ₹5 Final Dividend
Sun Pharma will hold its 34th AGM on July 31, 2026, via VC. The Record Date for a ₹5 final dividend for FY25-26 is July 7, 2026. Dividend payment is expected by August 7, 2026. Shareholders must submit TDS documents by July 7, 2026.
Read the summary - High impact
Sun Pharma Q4 FY26: Sales up 13.6% to ₹1,45,598 crore, Net Profit at ₹27,140 crore
Sun Pharma reported Q4 FY26 sales of ₹1,45,598 crore, up 13.6%, and net profit of ₹27,140 crore. Full-year FY26 sales were ₹5,82,000 crore, with a 16.1% rise in EBITDA to ₹1,77,314 crore. The company declared a total dividend of ₹16 per share for FY26. Innovative Medicines sales grew 20.1% in Q4, while India sales rose 14.8%.
Read the summary - Low impact
Sun Pharma to Participate in Multiple Investor Meetings in Early June
Sun Pharmaceutical Industries Limited will participate in several analyst and institutional investor meetings in Mumbai from June 1 to June 4, 2026. The events include the BofA India Conference, Morgan Stanley's India Investment Forum, and Citi India Conference. No UPSI will be disclosed.
Read the summary - Low impact
Sun Pharma Applies for Reclassification from Promoter Group to Public Category
Sun Pharma has applied to stock exchanges for reclassification from the Promoter Group to the Public category, as per SEBI regulations. The application was submitted on 26 May 2026.
Read the summary - Medium impact
Sun Pharma to Present Pivotal UNLOXCYT Data at ASCO 2026 Annual Meeting
Sun Pharma will present pivotal long-term follow-up data on UNLOXCYT™ (cosibelimab-ipdl) at the ASCO 2026 Annual Meeting on May 31, 2026. Investigator-reviewed data showed a 50% objective response rate, including 27% complete responses, with durable responses. Safety profile was manageable, with Grade ≥3 irAEs in 2% of patients.
Read the summary - Low impact
Sun Pharma to attend 360 ONE Capital's Investor Conference on May 27
Sun Pharma will attend 360 ONE Capital's 16th Annual Investor Conference, TRINITY INDIA 2026, on May 27, 2026, in Mumbai. The company will not disclose any Unpublished Price Sensitive Information during the group and one-on-one meetings.
Read the summary - Medium impact
SUNPHARMA Announces Audited Financial Results for Quarter and Year Ended March 31, 2026
Sun Pharmaceutical Industries Limited announced its audited financial results for the quarter and year ended March 31, 2026, in compliance with SEBI regulations. The results are available on the company's website and stock exchange platforms, as stated in a notification by Managing Director Kirti Ganorkar on May 22, 2026. Newspaper advertisements regarding the same were published on May 23, 2026.
Read the summary - Low impact
Sun Pharma Q4 FY26 Investor Call Audio Recording Available Online
Sun Pharma has released the audio recording of its investor call held on 22 May 2026. The recording is available on the company's website and follows the previous intimation about the earnings call.
Read the summary - Low impact
Sun Pharma Board Approves Promoter Reclassification & Revised Disclosure Code
Sun Pharma's Board approved reclassifying certain promoter group individuals to the public category, subject to regulatory approvals. They also adopted a revised Code of Fair Disclosure, effective June 1, 2026. The Board meeting concluded on May 22, 2026.
Read the summary - Medium impact
Sun Pharma Declares Final Dividend of ₹5 Per Share for FY26
Sun Pharmaceutical Industries Limited announced its audited financial results for the quarter and year ended March 31, 2026. The Board recommended a final dividend of ₹5 per equity share for FY 2025-26, subject to shareholder approval at the AGM.
Read the summary - Medium impact
Sun Pharma Board Approves FY26 Audited Results and Recommends Final Dividend of ₹5
Sun Pharma's Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. A final dividend of ₹5 per equity share is recommended for FY26, subject to AGM approval. The company also approved related press releases and earnings presentations.
Read the summary - Medium impact
Sun Pharma Board Approves FY26 Audited Results, Recommends Final Dividend of ₹5
Sun Pharma's Board approved audited standalone and consolidated financial results for FY26. They recommended a final dividend of ₹5 per share for FY25-26, pending shareholder approval at the AGM. The Board also approved related press releases and earnings presentations.
Read the summary - Low impact
Sun Pharma Announces Special Window for Physical Share Transfers
Sun Pharma is facilitating a special one-year window (Feb 5, 2026 - Feb 4, 2027) for transferring physical shares sold before April 1, 2019. Transferred shares will be in demat mode and locked in for one year. Advertisements were published on May 20, 2026.
Read the summary - Low impact
Sun Pharma Receives Reclassification Requests from Promoter Group Shareholders
Sun Pharma received reclassification requests from promoter group shareholders Mr. Sudhir Vrundavandas Valia and Mrs. Raksha Sudhir Valia. They collectively hold 4,31,75,371 shares (1.80%). The requests will be reviewed by the Board, subject to SEBI regulations.
Read the summary - Low impact
Sun Pharma to announce Q4 FY26 results on May 22, 2026; Earnings call same day
Sun Pharmaceutical Industries Limited will announce its Q4 FY26 results on May 22, 2026. An earnings call is scheduled for the same day at 06:30 pm IST, where management will discuss performance and answer questions.
Read the summary - Medium impact
Sun Pharma Appoints Dr. Andreas Busch as Independent Director; Ms. Satyavati Berera Joins Committees
Sun Pharma appointed Dr. Andreas Busch as an Independent Director for a five-year term starting 12 May 2026. Ms. Satyavati Berera has joined the Audit and Risk Management Committees from the same date. These changes follow the retirement of Ms. Rama Bijapurkar on 20 May 2026.
Read the summary - Low impact
Sun Pharma Appoints Ms. Satyavati Berera as Independent Director
Sun Pharma shareholders approved a resolution via postal ballot. Ms. Satyavati Berera has been appointed as an Independent Director for a five-year term, effective May 8, 2026. Voting results have been submitted to stock exchanges.
Read the summary - Medium impact
Sun Pharma's Long-Term Ratings Affirmed 'AAA' with Developing Implications by CRISIL, ICRA Affirms '[ICRA]AAA(Stable)'
CRISIL reaffirmed Sun Pharma's long-term bank facilities rating at ‘Crisil AAA’ and short-term at ‘Crisil A1+’, placing the long-term rating on ‘Rating Watch with Developing Implications’ due to the Organon & Co. acquisition. ICRA also reaffirmed ratings at ‘[ICRA]AAA(Stable)’ and ‘[ICRA]A1+’ after noting the acquisition.
Read the summary - High impact
Sun Pharma to Acquire Organon Business for ₹84,000 Crore, Expanding Global Footprint
Sun Pharma is acquiring the Organon business for $11.75 billion (approx. ₹97,700 crore), aiming to become a global pharmaceutical leader. The deal enhances its innovative medicine portfolio (27% of revenue) and established brands (51%). Expected synergies of $350 million over 2-4 years, primarily cost-driven. Deal to close in 6-9 months.
Read the summary - Low impact
Sun Pharma Posts Investor Call Recording on Organon & Co. Acquisition
Sun Pharma released the audio recording of an investor call concerning the acquisition of Organon & Co. The call was held on April 27, 2026, and the recording is available on the company's website.
Read the summary - High impact
Sun Pharma Acquires Organon & Co for $11.75 Billion, Expected Close Early 2027
Sun Pharma to acquire Organon & Co for $11.75 billion enterprise value. Expected to close in early 2027. Acquisition to strengthen Sun Pharma's global position in innovative medicines, women's health, and biosimilars. Combined entity to generate ~$12.4 billion revenue. Synergies of over $350 million anticipated.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio